FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2578778001> ?p ?o ?g. }

• W2578778001 abstract "Abstract In Italy the use of lenalidomide (LEN) in MDS with del(5q) is ruled by a national agency (AIFA, Agenzia Italiana del Farmaco) Registry since 2008. We conducted an observational, non-interventional, multi-centre, retrospective/prospective cohort study, registered as MORE (ClinicalTrials.gov NCT01347944), to investigate the use LEN in the context of a real world setting. Registry eligibility: IPSS low or intermediate-1 risk MDS with transfusion-dependent anemia and 5q31 deletion. MORE integration: retrospective collection of clinical, hematological and cytogenetic data at pre-registry time, at enrollment, after 4-6 cycles and 8-12 cycles of LEN, and at the last available follow-up and/or end of treatment. Hematological and cytogenetic response was assessed according to Cheson et al (Blood 2006). Statistical analysis used PL / SQL Developer and R open source software. 190 patients (M:F 60: 130) were included in this study (Table 1). GROUP A, (149 patients, median age 75 years) with complete data sets, and GROUP B (41 patients, median age 71 years), investigated only by FISH were analyzed separately. By integration of Registry with MORE forms, including disease history and/or treatment preceding inclusion in the Registry, information was recruited over a median time of 44 months (range 0.5-237). The complete erythroid response rate was 74.6% in group A and 78.6% in group B after 4-6 cycles treatment, and 85.8% and 88.9%, respectively after 8-12 cycles. The partial response rate was 11.5% in group A and 10.7% in group B at 4-6 months cycles. The complete cytogenetic response rate (only group A ) after 4-6 cycles was 7.8%. The partial response rate was 2.3 %. After 8-12 cycles complete response increased to 13% , partial response to 9.6 %. Leukemic evolution was observed in 18 cases (9.5%). Disease progression to a higher risk MDS was found in 12 cases (6.3%). Neutropenia (grade 3-4; 59%) and thrombocytopenia (grade 3-4; 21%) were predominant in the first 6 months of treatment. Infections (21%) mostly affected the upper respiratory tract. As far as we know this is the first report on LEN administration within a national registry. Despite being a retrospective study solid information on real life management of del(5q)-MDS were obtained. The known efficacy on erythropoiesis was strongly confirmed (FIG.1A). Notably, we also found a good response in low/int-1 IPSS cases with non-isolated 5q- (70.6%), suggesting that IPSS score plays a role in the successful response. The low rate of cytogenetic response possibly reflected the high level of variations in timing and dosage of LEN as well as heterogeneity of analyses in a non-centralized study. Nevertheless, results after 8-12 cycles (22.6%; FIG.1B) were similar to the 25% found with 5mg LEN in the European cooperative MDS004 study (Fenaux P et al, Blood 2011). AML evolution was found in 18/190 cases (9.6%) after a median of 7.5 LEN cycles (range 1-30). Moreover twelve additional cases (6.3%) showed progression to RAEB1 or RAEB2 after a median of 19.5 LEN cycles (range 4-56). In the MDS004 study a similar analysis gave 25.4 % of leukemic evolution and 2.9% of disease progression. This large series of MDS with del(5q) allowed us to confirm the efficacy of LEN in a real world setting. Biological and clinical features seem to be critical for the success of this personalized therapy. Table 1. Table 1. Figure 1. Clinical-hematological features of 190 cases (MORE Study). Figure 1. Clinical-hematological features of 190 cases (MORE Study). Disclosures Roncadori: Celgene: Research Funding. Rossi:Celgene: Research Funding. D'Emilio:Celgene: Research Funding. Di Renzo:Celgene: Research Funding. Leoni:Celgene: Research Funding. Rambaldi:Roche: Honoraria; Novartis: Honoraria; Amgen: Honoraria; Celgene: Research Funding; Pierre Fabre: Honoraria. Avanzini:Celgene: Research Funding. Visani:Celgene: Research Funding. Tura:Celgene: Research Funding. Covezzoli:Celgene: Research Funding. Mecucci:Celgene: Research Funding." @default.
• W2578778001 created "2017-01-26" @default.
• W2578778001 creator A5001967659 @default.
• W2578778001 creator A5011614506 @default.
• W2578778001 creator A5016148789 @default.
• W2578778001 creator A5019219622 @default.
• W2578778001 creator A5024306596 @default.
• W2578778001 creator A5028165355 @default.
• W2578778001 creator A5028913158 @default.
• W2578778001 creator A5030254190 @default.
• W2578778001 creator A5033359713 @default.
• W2578778001 creator A5034123305 @default.
• W2578778001 creator A5055401685 @default.
• W2578778001 creator A5057084037 @default.
• W2578778001 creator A5067245102 @default.
• W2578778001 creator A5074396899 @default.
• W2578778001 creator A5074895768 @default.
• W2578778001 creator A5075320520 @default.
• W2578778001 creator A5087980211 @default.
• W2578778001 date "2015-12-03" @default.
• W2578778001 modified "2023-09-28" @default.
• W2578778001 title "Use of Lenalidomide in DEL(5q) MDS. a National AIFA (Agenzia Italiana del Farmaco) Registry Study" @default.
• W2578778001 doi "https://doi.org/10.1182/blood.v126.23.1693.1693" @default.
• W2578778001 hasPublicationYear "2015" @default.
• W2578778001 type Work @default.
• W2578778001 sameAs 2578778001 @default.
• W2578778001 citedByCount "1" @default.
• W2578778001 countsByYear W25787780012016 @default.
• W2578778001 crossrefType "journal-article" @default.
• W2578778001 hasAuthorship W2578778001A5001967659 @default.
• W2578778001 hasAuthorship W2578778001A5011614506 @default.
• W2578778001 hasAuthorship W2578778001A5016148789 @default.
• W2578778001 hasAuthorship W2578778001A5019219622 @default.
• W2578778001 hasAuthorship W2578778001A5024306596 @default.
• W2578778001 hasAuthorship W2578778001A5028165355 @default.
• W2578778001 hasAuthorship W2578778001A5028913158 @default.
• W2578778001 hasAuthorship W2578778001A5030254190 @default.
• W2578778001 hasAuthorship W2578778001A5033359713 @default.
• W2578778001 hasAuthorship W2578778001A5034123305 @default.
• W2578778001 hasAuthorship W2578778001A5055401685 @default.
• W2578778001 hasAuthorship W2578778001A5057084037 @default.
• W2578778001 hasAuthorship W2578778001A5067245102 @default.
• W2578778001 hasAuthorship W2578778001A5074396899 @default.
• W2578778001 hasAuthorship W2578778001A5074895768 @default.
• W2578778001 hasAuthorship W2578778001A5075320520 @default.
• W2578778001 hasAuthorship W2578778001A5087980211 @default.
• W2578778001 hasConcept C126322002 @default.
• W2578778001 hasConcept C151730666 @default.
• W2578778001 hasConcept C167135981 @default.
• W2578778001 hasConcept C187212893 @default.
• W2578778001 hasConcept C2776063141 @default.
• W2578778001 hasConcept C2776364478 @default.
• W2578778001 hasConcept C2779343474 @default.
• W2578778001 hasConcept C71924100 @default.
• W2578778001 hasConcept C86803240 @default.
• W2578778001 hasConceptScore W2578778001C126322002 @default.
• W2578778001 hasConceptScore W2578778001C151730666 @default.
• W2578778001 hasConceptScore W2578778001C167135981 @default.
• W2578778001 hasConceptScore W2578778001C187212893 @default.
• W2578778001 hasConceptScore W2578778001C2776063141 @default.
• W2578778001 hasConceptScore W2578778001C2776364478 @default.
• W2578778001 hasConceptScore W2578778001C2779343474 @default.
• W2578778001 hasConceptScore W2578778001C71924100 @default.
• W2578778001 hasConceptScore W2578778001C86803240 @default.
• W2578778001 hasLocation W25787780011 @default.
• W2578778001 hasOpenAccess W2578778001 @default.
• W2578778001 hasPrimaryLocation W25787780011 @default.
• W2578778001 hasRelatedWork W2264283791 @default.
• W2578778001 hasRelatedWork W2406703107 @default.
• W2578778001 hasRelatedWork W2551315696 @default.
• W2578778001 hasRelatedWork W2553096950 @default.
• W2578778001 hasRelatedWork W2559684060 @default.
• W2578778001 hasRelatedWork W2560214822 @default.
• W2578778001 hasRelatedWork W2565869983 @default.
• W2578778001 hasRelatedWork W2566144296 @default.
• W2578778001 hasRelatedWork W2570740377 @default.
• W2578778001 hasRelatedWork W2574206479 @default.
• W2578778001 hasRelatedWork W2576790760 @default.
• W2578778001 hasRelatedWork W2577042196 @default.
• W2578778001 hasRelatedWork W2581800887 @default.
• W2578778001 hasRelatedWork W2586170948 @default.
• W2578778001 hasRelatedWork W2605528715 @default.
• W2578778001 hasRelatedWork W2732965047 @default.
• W2578778001 hasRelatedWork W2899218628 @default.
• W2578778001 hasRelatedWork W2979701720 @default.
• W2578778001 hasRelatedWork W3137406227 @default.
• W2578778001 hasRelatedWork W613303972 @default.
• W2578778001 isParatext "false" @default.
• W2578778001 isRetracted "false" @default.
• W2578778001 magId "2578778001" @default.
• W2578778001 workType "article" @default.